Drilldown: Medicines

Desvenlafaxine (succinate) (1) · Latanoprost (1)

Pristiq (1) · Xalatan, Xelpros (1)

[[:Category:Antidepressants|Antidepressant]] (1) · [[:Category:Glaucoma_medications|Glaucoma medication]] (1) · [[:Category:Ocular_hypotensive_agents|Ocular hypotensive agent]] (1) · [[:Category:Prostaglandin_analogs|Prostaglandin F2α analog]] (1) · [[:Category:SNRIs|Serotonin-norepinephrine reuptake inhibitor (SNRI)]] (1)

None (2)

'"`UNIQ--vote-00000017-QINU`"', '"`UNIQ--vote-00000018-QINU`"', '"`UNIQ--vote-00000019-QINU`"' (1) · '"`UNIQ--vote-00000415-QINU`"', '"`UNIQ--vote-00000416-QINU`"' (1)

1 drop in the affected eye(s) once daily in the evening (1) · 50 mg PO once daily ('''no titration required''', distinguishing it favorably from venlafaxine) (1)

0.005% ophthalmic solution (50 mcg/mL); typical 2.5 mL bottle (1) · ER tablets 25, 50, 100 mg (1)

1 drop/eye/day (more frequent dosing reduces efficacy) (1) · 50 mg/day (no efficacy benefit shown for higher doses despite the 100 mg strength being available) (1)

Oral (1) · Topical ophthalmic (1)

None · Hours · 30-60 minutes · 1-2 hours · ~30 min · LDL lowering at 2 weeks, max by 4 weeks · ~1 hour · 15-30 minutes · 15–30 min · 1–2 h · 30–60 min · Antidepressant effect emerges over 1-2 weeks · BP and symptomatic LUTS improvement within 1-2 weeks · BP effect within 1-2 weeks · Clinical improvement within 24-72 hours · Days · Motor improvement over days at therapeutic dose · Over weeks · Postprandial glucose effect within days; HbA1c by 12 weeks · Sleep effect from first dose; antidepressant effect over 1-4 weeks

Other values:

Search

None · 24 hours · 4-6 hours · 12 hours · 6-8 hours · Daily dosing · 8-12 hours · 12-24 hours · Hours · Hours per application · 24 hours (HS dosing) · 24 hours (once-daily dosing) · 24 h · N/A · N/A (replacement) · Variable · ~7-8 hours · 3-5 hours · 4-6 hours (IR); 24 hours (ER) · 6-12 hours

Other values:

Search

~11 hours'"`UNIQ--ref-0000001A-QINU`"' (1) · ~17 minutes (free acid, the active form, in aqueous humor)'"`UNIQ--ref-00000417-QINU`"' (1)

Topical; minimal systemic absorption'"`UNIQ--ref-00000418-QINU`"' (1) · ~80% (oral)'"`UNIQ--ref-0000001B-QINU`"' (1)

Limited data; weigh against alternatives, though systemic exposure is low.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Observational signal for neonatal adaptation syndrome with late-pregnancy exposure (SNRI class effect).<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1)

[[USLegal:Prescription only|Rx-only]] in US (1) · [[USLegal:Prescription only|Rx-only]] in US. Carries the antidepressant '''Boxed Warning''' for suicidality in children, adolescents, and young adults'"`UNIQ--ref-0000001C-QINU`"' (1)